South Dakota Investment Council lowered its position in shares of Kenvue Inc. (NYSE:KVUE – Free Report) by 9.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 386,353 shares of the company’s stock after selling 39,600 shares during the quarter. South Dakota Investment Council’s holdings in Kenvue were worth $6,823,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. BlackRock Inc. bought a new position in shares of Kenvue in the 2nd quarter worth about $2,882,279,000. Pentwater Capital Management LP bought a new stake in shares of Kenvue during the 2nd quarter valued at about $977,094,000. HBK Investments L P grew its stake in Kenvue by 33.3% during the second quarter. HBK Investments L P now owns 28,000,001 shares of the company’s stock worth $535,080,000 after purchasing an additional 7,000,000 shares during the period. Dimensional Fund Advisors LP increased its holdings in Kenvue by 0.9% in the first quarter. Dimensional Fund Advisors LP now owns 22,270,175 shares of the company’s stock worth $383,938,000 after purchasing an additional 196,981 shares in the last quarter. Finally, Amundi increased its holdings in Kenvue by 41.2% in the second quarter. Amundi now owns 18,483,326 shares of the company’s stock worth $353,216,000 after purchasing an additional 5,392,413 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.
Kenvue Price Performance
Shares of NYSE:KVUE opened at $19.31 on Thursday. The business’s 50 day simple moving average is $18.51 and its two-hundred day simple moving average is $18.31. The firm has a market cap of $37.09 billion, a P/E ratio of 21.94, a PEG ratio of 1.77 and a beta of 0.48. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01. Kenvue Inc. has a 52-week low of $14.06 and a 52-week high of $20.13.
Kenvue (NYSE:KVUE – Get Free Report) last announced its quarterly earnings data on Friday, October 30th. The company reported $0.29 EPS for the quarter, meeting analysts’ consensus estimates of $0.29. The firm had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.86 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%. The company’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.28 earnings per share. As a group, research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.
Kenvue Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Friday, October 2nd. Investors of record on Monday, September 21st were given a $0.21 dividend. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.84 annualized dividend and a yield of 4.4%. Kenvue’s dividend payout ratio (DPR) is presently 95.45%.
Wall Street Analysts Forecast Growth
A number of research firms have issued reports on KVUE. HSBC cut their price target on Kenvue from $20.00 to $19.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Wall Street Zen downgraded shares of Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. UBS Group boosted their target price on shares of Kenvue from $19.00 to $20.00 and gave the company a “neutral” rating in a research report on Monday, November 2nd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Kenvue in a research note on Friday, September 11th. Ten analysts have rated the stock with a Hold rating. Based on data from MarketBeat, Kenvue currently has an average rating of “Hold” and an average price target of $19.29.
Get Our Latest Report on Kenvue
Kenvue Company Profile
Kenvue Inc. is a consumer health company that develops and sells products for everyday health and personal care. Its portfolio includes over-the-counter medicines, skin and hair care, oral care, wound care, and baby care products. Its well-known brands include Tylenol, Neutrogena, Aveeno, Listerine, Band-Aid, Johnson’s, and Zyrtec. Kenvue organizes its business around Self Care, Skin Health and Beauty, and Essential Health. The company became an independent business in 2023 after Johnson & Johnson completed the separation of its consumer health business.
Recommended Stories
- Five stocks we like better than Kenvue
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
